MyFinsight
Home
Compare
About
Recent SEC Filings
10/2
NIKE, Inc.
(NKE)
10/2
DARDEN RESTAURANTS INC
(DRI)
9/30
CONAGRA BRANDS INC.
(CAG)
9/29
Carnival Corp Ltd.
(CCL)
9/29
URANIUM ENERGY CORP
(UEC)
9/29
COPART INC
(CPRT)
9/24
BLACKBERRY Ltd
(BB)
9/24
PAYCHEX INC
(PAYX)
9/23
GENERAL MILLS INC
(GIS)
9/22
ADOBE INC.
(ADBE)
9/18
KROGER CO
(KR)
10/2
NIKE, Inc.
(NKE)
10/2
DARDEN RESTAURANTS INC
(DRI)
9/30
CONAGRA BRANDS INC.
(CAG)
9/29
Carnival Corp Ltd.
(CCL)
9/29
URANIUM ENERGY CORP
(UEC)
9/29
COPART INC
(CPRT)
9/24
BLACKBERRY Ltd
(BB)
9/24
PAYCHEX INC
(PAYX)
9/23
GENERAL MILLS INC
(GIS)
9/22
ADOBE INC.
(ADBE)
9/18
KROGER CO
(KR)
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
|
Compare
Balance Sheets Overview
Current Ratio
100.00%
Quick Ratio
100.00%
Cash Ratio
78.98%
Debt to Asset Ratio
91.15%
Unit: Dollar
Assets Breakdown
Cash and cash equivalents
Operating lease right-of-use ass...
Short-term investments
Others
Liabilities Breakdown
Additional paid-in capital
Accumulated deficit
Common stock warrant liabilities
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Balance Sheets
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Cash and cash equivalents
31,526,164
26,271,650
44,273,319
36,567,420
Short-term investments
5,147,853
11,409,607
14,239,145
14,235,770
Accounts receivable from affiliated entity
-
-
-
978,590
Prepaid expenses and other current assets, including from affiliated entity
3,239,232
1,758,348
2,610,882
3,398,534
Total current assets
39,913,249
39,439,605
61,123,346
55,180,314
Fixed assets, net
1,888,725
2,210,759
2,527,603
2,740,356
Investments in affiliated entity
0
0
2,103,688
2,495,730
Operating lease right-of-use assets
5,670,451
6,114,303
6,542,923
6,956,780
Other assets
1,917,069
2,012,475
2,012,475
2,012,476
Total assets
49,389,494
49,777,142
74,310,035
69,385,656
Accounts payable and accrued expenses-Nonrelated Party
11,653,162
9,267,415
11,053,618
15,323,520
Accounts payable and accrued expenses-Related Party
0
0
74,473
379,721
Accrued clinical trial expenses
338,461
817,331
650,680
955,970
Common stock warrant liabilities
25,024,799
24,929,459
29,067,162
50,384,043
Operating lease liability
2,898,637
2,908,820
2,822,622
2,738,490
Grant funding liability from affiliated entity
-
-
-
42,152
Total current liabilities
39,915,059
37,923,025
43,668,555
69,823,896
Operating lease liability, net of current portion
5,103,352
5,786,235
6,545,204
7,281,737
Total liabilities
45,018,411
43,709,260
50,213,759
77,105,633
Preferred stock
0
0
-
0
Common stock
82,342
69,773
68,997
53,572
Additional paid-in capital
1,845,429,136
1,841,482,163
1,839,830,405
1,811,803,850
Accumulated deficit
-1,840,860,419
-1,834,847,961
-1,815,165,163
-1,818,930,043
Accumulated other comprehensive loss
-279,976
-636,093
-637,963
-647,356
Total inovio pharmaceuticals, inc. stockholders equity
4,371,083
6,067,882
24,096,276
-7,719,977
Total liabilities and stockholders equity
49,389,494
49,777,142
74,310,035
69,385,656
Page 1
Unit: Dollar. Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Balance Sheets
INO Balance Sheet Sankey Diagram
Sankey diagram visualizing INO balance sheet for the period
Cash and cash
equivalents
$31,526,164
(29.46%↑ Y/Y)
Short-term investments
$5,147,853
(-77.81%↓ Y/Y)
Prepaid expenses and
other current assets,...
$3,239,232
(-24.80%↓ Y/Y)
Total current assets
$39,913,249
(-24.26%↓ Y/Y)
Operating lease
right-of-use assets
$5,670,451
(-22.92%↓ Y/Y)
Other assets
$1,917,069
(-4.74%↓ Y/Y)
Fixed assets, net
$1,888,725
(-38.86%↓ Y/Y)
Total assets
$49,389,494
(-27.62%↓ Y/Y)
Total liabilities and
stockholders equity
$49,389,494
(-27.62%↓ Y/Y)
Total liabilities
$45,018,411
(13.37%↑ Y/Y)
Total inovio
pharmaceuticals, inc....
$4,371,083
(-84.68%↓ Y/Y)
Accumulated deficit
-$1,840,860,419
(-3.80%↓ Y/Y)
Accumulated other
comprehensive loss
-$279,976
(57.69%↑ Y/Y)
Total current
liabilities
$39,915,059
(25.88%↑ Y/Y)
Operating lease
liability, net of current...
$5,103,352
(-36.22%↓ Y/Y)
Additional paid-in capital
$1,845,429,136
(2.38%↑ Y/Y)
Common stock
$82,342
(124.25%↑ Y/Y)
Common stock warrant
liabilities
$25,024,799
(119.13%↑ Y/Y)
Accounts payable and
accrued...
$11,653,162
(-26.01%↓ Y/Y)
Operating lease liability
$2,898,637
(9.13%↑ Y/Y)
Accrued clinical trial
expenses
$338,461
(-77.60%↓ Y/Y)
Buy us a coffee
INOVIO PHARMACEUTICALS, INC. (INO)
INOVIO PHARMACEUTICALS, INC. (INO)